Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 1.00 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 1.00 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 1.00 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 1.00 |
| ▸ | DPP4 | P27487 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | GAPDH | P04406 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | PI4KA | P42356 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 1.00 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL14496806 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL10361572 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL110914 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL20399009 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL24538665 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2028876 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23804425 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23420216 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL4403412 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL329845 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0098186-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PURINE OR PYRIMIDINE XYLOSIDES AND LYXOSIDES | SYNTHELABO (FR) | 1987-09-16 | — | — | EP | claimed |
| US-4659698-A | Pharmaceutical compositions based on xylosides and lyxosides of purine and pyrimidine bases used in a method of treating viruses | SYNTHELABO (FR) | 1987-04-21 | — | — | US | claimed |
| US-20230102924-A1 | Methods of Treating Cancer Using Checkpoint Inhibitors in Combination with Purine Cleaving Enzymes | UNIV EMORY (US) | 2023-03-30 | — | — | US | disclosed |
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-03-07 | — | — | US | disclosed |
| US-11339441-B2 | Profiling chemically modified DNA/RNA units for disease and cancer diagnosis | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210292761-A1 | COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2021-09-23 | — | — | US | disclosed |
| US-20210284679-A1 | ß-Modified Phosphoric Acid Compound Precursor, ß-Modified Phosphoric Acid Compound, Reaction Inhibitor and Medicine Containing the Same, and Method for Inhibiting Reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2021-09-16 | — | — | US | disclosed |
| US-20210220233-A1 | COSMETIC COMPOSITIONS | ALLUSTRA TECHNOLOGIES LLC | 2021-07-22 | — | — | US | disclosed |
| US-10881699-B2 | Cosmetic compositions | MARY KAY INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200323892-A1 | METHODS FOR TREATMENT USING SMALL MOLECULE POTASSIUM-SPARING DIURETICS AND NATRIURETICS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-10-15 | — | — | US | disclosed |
| US-10729711-B2 | Methods for treatment using small molecule potassium-sparing diuretics and natriuretics | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-08-04 | — | — | US | disclosed |
| US-5939402-A | TREATING PLASMODIUM, VIRAL INFECTIONS OR PARASITES IN MAMMALS | LIPITEK INTERNATIONAL, INC. (US) | 1999-08-17 | — | — | US | disclosed |
| EP-0793669-A4 | L-NUCLEOSIDE DIMER COMPOUNDS AND THERAPEUTIC USES | LIPITEK INTERNATIONAL INC (US) | 1999-02-03 | — | — | EP | disclosed |
| EP-0793669-A1 | L-NUCLEOSIDE DIMER COMPOUNDS AND THERAPEUTIC USES | Lipitek International, Inc. (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1997011087-A1 | L-NUCLEOSIDE DIMER COMPOUNDS AND THERAPEUTIC USES | LIPITEK INTERNATIONAL, INC. (US) | 1997-03-27 | — | — | WO | disclosed |
| US-5506347-A | ADENOSINE KINASE INHIBITOR | GENSIA, INC. (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0684953-A1 | ADENOSINE KINASE INHIBITORS COMPRISING LYXOFURANOSYL DERIVATIVES | GENSIA, INC. (US) | 1995-12-06 | — | — | EP | disclosed |
| WO-1994018215-A1 | ADENOSINE KINASE INHIBITORS COMPRISING LYXOFURANOSYL DERIVATIVES | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| US-4659698-A | Pharmaceutical compositions based on xylosides and lyxosides of purine and pyrimidine bases used in a method of treating viruses | SYNTHELABO (FR) | 1987-04-21 | — | — | US | disclosed |
| US-4659698-A | Pharmaceutical compositions based on xylosides and lyxosides of purine and pyrimidine bases used in a method of treating viruses | SYNTHELABO (FR) | 1987-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323892-A1 | METHODS FOR TREATMENT USING SMALL MOLECULE POTASSIUM-SPARING DIURETICS AND NATRIURETICS | PNP, SLC28A1, SLC28A2 | ADORA3 302/4885ADORA2A 519/4885ADORA2B 725/4885 |
| US-20210220233-A1 | COSMETIC COMPOSITIONS | TYR, MC1R, GLA | ADORA3 3451/4885ADORA2A 3455/4885ADORA2B 3536/4885 |
| US-20210292761-A1 | COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOF | POLI, POLN, POLRMT | ADORA3 605/4885ADORA2A 1144/4885ADORA2B 900/4885 |
| US-10729711-B2 | Methods for treatment using small molecule potassium-sparing diuretics and natriuretics | PNP, GMPS, SLC5A1 | ADORA3 588/4885ADORA2A 756/4885ADORA2B 1178/4885 |
| US-10881699-B2 | Cosmetic compositions | MC1R, TYR, TNF | ADORA3 4179/4885ADORA2A 2656/4885ADORA2B 3195/4885 |
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | PPM1A, PPM1G, PPM1F | ADORA3 2415/4885ADORA2A 1474/4885ADORA2B 1076/4885 |
| US-20210284679-A1 | ß-Modified Phosphoric Acid Compound Precursor, ß-Modified Phosphoric Acid Compound, Reaction Inhibitor and Medicine Containing the Same, and Method for Inhibiting Reaction | IRS1, PPM1A, PPM1G | ADORA3 2340/4885ADORA2A 1332/4885ADORA2B 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.